Skip to main content

Affy Shares Up 6.3 Percent After Firm Reports Need to Restate Certain Financial Reports

NEW YORK (GenomeWeb News) - Shares in Affymetrix were up 6.25, or $1.20, at $20.41 in mid-afternoon share after the company late yesterday said it would have to restate its financial results as far back as 1997 after an internal review into its stock-option granting practices turned up “certain documentation lapses.”
 
As GenomeWeb News reported this morning, the company said yesterday that the restatements will increase its previously reported net losses from 1997 to 2002, reduce its previously reported net income for 2003, and increase its previously reported net income in 2005.
 
In a statement, Affy said financial information in its Form 10-Q for the three months ended March 31 and its Form 10-K for the full year ended Dec. 31, 2005, “should no longer be relied upon.”
 
Affymetrix said it expects to file restated financial reports with the US Securities and Exchange Commission during the current quarter. It also has delayed filing second-quarter results.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.